4’-Thionucleosides as adenosine A3 receptor ligands: a medicinal chemistry perspective
Medicinal Chemistry Research · 2026
DOI: 10.1007/s00044-026-03560-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Chemistry Research, 2026. Verfasst von Hong-Rae Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. hrkim07@korea.ac.kr. Hauptthemen laut MEDLINE: Receptor, Adenosine A3, Thionucleosides, Adenosine A3 Receptor Antagonists. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT Future Planning.
Abstract (Originalsprache)
The adenosine A3 receptor (A3AR) is recognized as a potential therapeutic target across multiple human pathologies; however, the development of selective orthosteric ligands remains challenging due to receptor subtype conservation and species-dependent pharmacology. Among nucleoside-derived chemotypes, 4'-thionucleosides, generated by bioisosteric replacement of the ribose endocyclic oxygen with sulfur, constitute a synthetically accessible scaffold for modulating A3AR activity. This review summarizes synthetic methodologies that have enabled systematic diversification of the 4'-thio chemotype, including β-selective N-glycosylation and de novo cyclization strategies, and analyzes structure-activity relationships (SAR) associated with modifications at the N6, C2, and 5' positions, as well as ribose truncation. These structural variations have been correlated with changes in binding affinity, subtype selectivity, and intrinsic efficacy, supporting the utility of the 4'-thio scaffold in generating distinct pharmacological profiles. The recent availability of cryo-electron microscopy structures of human A3AR, including active agonist-bound states and, more recently, an inactive antagonist-bound conformation, provides a structural context for interpretation of established SAR trends and may facilitate future structure-guided and modeling-informed ligand optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. hrkim07@korea.ac.kr.
- Center for Innovative Drug Discovery, Korea University Anam Hospital, Seoul, Republic of Korea. hrkim07@korea.ac.kr.
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Republic of Korea. lakjeong@snu.ac.kr.
- Future Medicine Company Limited, Seoul, Republic of Korea. lakjeong@snu.ac.kr.
Förderung
- National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT Future Planning
Zitieren
APA
Kim, H. R., & Jeong, L. S. (2026). 4’-Thionucleosides as adenosine A3 receptor ligands: a medicinal chemistry perspective. Medicinal Chemistry Research. https://doi.org/10.1007/s00044-026-03560-3
Vancouver
Kim HR, Jeong LS. 4’-Thionucleosides as adenosine A3 receptor ligands: a medicinal chemistry perspective. Medicinal Chemistry Research. 2026. doi:10.1007/s00044-026-03560-3
BibTeX
@article{Kim2026,
author = {Kim, Hong-Rae and Jeong, Lak Shin},
title = {4’-Thionucleosides as adenosine A3 receptor ligands: a medicinal chemistry perspective},
journal = {Medicinal Chemistry Research},
year = {2026},
doi = {10.1007/s00044-026-03560-3}
}
EUVIMED